Cariprazine
- Generic Name
- Cariprazine
- Brand Names
- Vraylar, Reagila
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32Cl2N4O
- CAS Number
- 839712-12-8
- Unique Ingredient Identifier
- F6RJL8B278
- Background
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipo...
- Indication
Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depressio...
- Associated Conditions
- Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
- Associated Therapies
- -
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Intra-Cellular Therapies seeks FDA approval for Caplyta as an adjunct treatment for major depressive disorder (MDD), potentially expanding its market to over $1 billion. Caplyta, already approved for schizophrenia and bipolar disorder, saw Q3 sales of $175 million, with Q4 projections at least $193 million. The MDD submission is based on Phase III trials showing symptom improvement when paired with an antidepressant. Jefferies estimates a 90–95% approval likelihood, predicting a company valuation of $9–12 billion. Intra-Cellular is also exploring Caplyta for autism and developing ITI-214 for Parkinson’s and ITI-333 for opioid use.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
AbbVie (NYSE: ABBV), Realty Income (NYSE: O), and Verizon Communications (NYSE: VZ) are recommended for long-term passive income due to their consistent dividend growth and strong financial positions.
Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline
New treatments like COMP360, Zuranolone, LY03005, REL-1017, Seltorexant, and ABV-1504 are expected to significantly transform the major depressive disorder (MDD) market. MDD affects 44 million diagnosed cases in the 7MM, with moderate cases being the most prevalent. Treatment approaches include pharmacological interventions, psychotherapy, and lifestyle changes. The market size for MDD is projected to grow from USD 7.1 billion in 2023, driven by disease awareness and new product launches.
AbbVie's $9B bet collapses as closely watched schizophrenia drug fails studies
AbbVie lost $40 billion in market value after its experimental drug emraclidine failed two clinical trials for schizophrenia. Despite the setback, AbbVie remains focused on neuroscience and has a diverse portfolio of brain medicines. The failure of emraclidine removes a competitive threat for Bristol Myers' Cobenfy, an approved antipsychotic.
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
AbbVie's phase 2 trials for schizophrenia treatment, emraclidine, missed primary endpoint, causing share decline. Despite disappointment, AbbVie continues data analysis and remains committed to psychiatric and neurological disorder treatments.
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings
Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.
AbbVie, Gedeon Richter Ink Deal to Develop Novel Targets for Neuropsychiatric Conditions
AbbVie and Gedeon Richter expand their neuropsychiatric collaboration, aiming to discover and develop novel targets. The partnership includes preclinical and clinical R&D activities, with Richter receiving an upfront payment of $25 million and potential milestone payments. Vraylar, a product of their previous collaboration, has been approved for schizophrenia, bipolar I disorder, major depressive disorder, and as adjunctive therapy for MDD. The prevalence of mental illness in the U.S. in 2022 was over 20%, highlighting the need for new therapies.
Anxiety Disorders and Depression Treatment Market to Reach
The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.
FTC's watchdog role in pharma mergers: Road bumps and the way forward
The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.
Bristol Myers gets USFDA nod for new type of schizophrenia drug
Bristol Myers Squibb receives FDA approval for Cobenfy, a new antipsychotic drug for schizophrenia, the first in decades. Cobenfy, also known as KarXT, lacks warnings about increased mortality in elderly patients and common side effects like weight gain and movement disorders. Bristol Myers expects $2.5 billion in U.S. sales by 2030 and plans to launch the drug at $1,850 a month. The approval is based on studies showing significant symptom reduction, targeting cholinergic receptors instead of dopamine. Cobenfy's side effects include vomiting and nausea, and it is not recommended for patients with urinary retention or severe kidney/liver disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath